文献速递儿童青少年精神

孤独症谱系障碍的临床神经科学新进展:综述

The Emerging Clinical Neuroscience of Autism Spectrum Disorder: A Review.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

本文综述孤独症谱系障碍(ASD)的临床神经科学进展,指出ASD行为学诊断背后涉及多种遗传与环境风险因素,产前脑发育对基因突变或药物暴露尤为敏感。神经影像可在6月龄检出脑连接改变,动物与细胞模型有助于定义分子细胞变化,精准医学希望按遗传风险亚型匹配治疗。

要点

  • ASD为行为学诊断,多种遗传与环境风险因素可单独或共同致病。
  • 产前脑发育对基因突变或药物暴露等风险因素尤为敏感。
  • 按遗传风险因素亚型化可能是实现精准治疗的可操作路径。

核心结论

  • 下一代测序、先进成像与分子建模技术使ASD风险相关生物通路和环路得以定义,可能首次将不同风险因素统一为共同神经生物学机制。
  • 从机制到改善孤独症个体生活的生物治疗路径仍不明确,但多线研究累积提示按遗传风险因素亚型化可能利用个体差异匹配特定治疗。

研究设计与样本

  • 本文为综述,围绕一名符合ASD标准学龄前儿童的易激惹与自伤常规评估案例,讨论当前可影响临床实践的研究途径并预览未来可能产出生物治疗的研究。

主要发现

  • ASD诊断基于行为,许多遗传和环境风险因素单独或共同与ASD相关。
  • 产前脑发育期对基因突变或药物暴露等影响脑发育和环路形成的风险因素尤为敏感。
  • 神经影像研究者可检测到6月龄ASD儿童的脑连接改变,随后至学龄前呈非典型脑发育轨迹并持续终生连接效率不足。
  • 动物和细胞模型系统为定义ASD风险因素相关分子和细胞变化提供了手段。
  • 精准医学的核心希望是将特定治疗与ASD特定亚群人群相连。

临床怎么用

  • 社区精神科医生在临床实践中可能诊治许多ASD个体,应了解当前可影响临床实践的研究途径。
  • 临床评估ASD儿童易激惹与自伤时,需关注染色体缺失和早产等已知ASD风险因素。

局限性

  • 从机制到生物治疗的路径仍不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autism spectrum disorder (ASD) is a highly prevalent disorder, and community psychiatrists are likely to treat many individuals with ASD during their clinical practice. This clinical case challenge describes a routine evaluation of irritability and self-injury in a preschool-aged child who meets the criteria for ASD. The case also illustrates the importance of known risk factors for ASD, such as chromosomal deletion and prematurity. This clinical neuroscience article seeks to educate the clinician of current avenues of research that can inform and may already affect clinical practice for this patient, while providing a preview of research that may yield biological treatments for ASD within the next decade. OBSERVATIONS: A diagnosis of ASD is defined behaviorally; therefore, many genetic and environmental risk factors, working singly or in concert, are linked to ASD. The prenatal period of brain development is particularly sensitive to risk factors such as gene mutation or drug exposure that affect brain development and circuitry formation. Currently, neuroimaging researchers can detect changes in brain connectivity of children with ASD as young as 6 months, followed by an atypical trajectory of brain development through preschool age and ongoing connectivity inefficiencies across the lifespan. Animal and cellular model systems have provided a means for defining the molecular and cellular changes associated with risk factors for ASD. The ability to connect specific treatments to particular subgroups of people with ASD is the defining hope of precision medicine initiatives. CONCLUSIONS AND RELEVANCE: The advent of next-generation sequencing technology, advanced imaging techniques, and cutting-edge molecular techniques for modeling ASD has allowed researchers to define ASD risk-related biological pathways and circuits that may, for the first time, unify the effects of disparate risk factors into common neurobiological mechanisms. The path from these mechanisms to biological treatments that improve the lives of individuals with autism remains unclear, but the cumulative output of multiple lines of research suggests that subtyping by genetic risk factors may be a particularly tractable way to capitalize on individual differences amenable to specific treatments.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Muhle RA, Reed HE, Stratigos KA, et al. The Emerging Clinical Neuroscience of Autism Spectrum Disorder: A Review. JAMA Psychiatry. 2018. PMID: 29590280. doi:10.1001/jamapsychiatry.2017.4685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。